Molecular prognostic factors in patients with pancreatic cancer

Bibliography

• PARKIN DM, BRAY FI, DEVESA SS: Cancer burden in the year 2000. The global picture. Eur. J. Cancer (2001) 37:4-66.
   PubMed Web of Science ®Google Scholar
• JEMAL A, MURRAY T, SAMUELS A et al.: Cancer statistics, 2003. CA Cancer J. Clin. (2003) 53:5-26.
   PubMed Web of Science ®Google Scholar
• SENER S, FRENGEN A, MENCK HR, WINCHESTER DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985 – 1995, using the National cancer database. J. Am. Coll. Surg. (1999) 189:1-7.
   PubMed Web of Science ®Google Scholar
• WEINBERG RA: Oncogenes, antioncogenes and the molecular basis of multistep carcinogenesis. Cancer Res. (1989) 49:3713-3719.
   PubMed Web of Science ®Google Scholar
• PILLAI R: Oncogenes and oncoproteins as tumor markers. Eur. J. Surg. Oncol. (1992) 18:417-424.
   PubMedGoogle Scholar
• WEINBERG RA: Tumor suppressor genes. Science (1991) 254:1138-1142.
   PubMed Web of Science ®Google Scholar
• SKUSE GR, LUDLOW JW: Tumor suppressor genes in disease and therapy. Lancet (1995) 345:902-906.
   PubMed Web of Science ®Google Scholar
• KIRSCH DG, KASTAN MB: Tumor-suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol. (1998) 16:3158-3168.
   PubMed Web of Science ®Google Scholar
• LIEBERMANN DA, HOFFMAN B, STEINMAN RA: Molecular controls of growth arrest and apoptosis: p53-dependent and independent markers. Oncogene (1995) 11:199-210.
   PubMed Web of Science ®Google Scholar
• DEPPERT W, GOHLER T, KOGA H, KIM E: Mutant p53: “gain of function” through perturbation of nuclear structure and function? J. Cell Biochem. Suppl. (2000) 35:115-122.
   PubMedGoogle Scholar
• MOORE PS, SIPOS B, ORLANDINI S et al.: Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virc. Arch. (2001) 439:798-802.
   PubMed Web of Science ®Google Scholar
• NAKA, KOBAYASHI M, ASHIDA K et al.: Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int. J. Oncol. (1998) 125:1111-1116.
   PubMed Web of Science ®Google Scholar
• NIO Y, DONG M, UEGAKI K et al.: Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas. Pancreas (1999) 18(2):117-126.
   PubMedGoogle Scholar
• DIGIUSEPPE A, HRUBAN RH, GOODMAN SN et al.: Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol. (1994) 101:684-688.
   PubMed Web of Science ®Google Scholar
• MAKINEN K, HAKALA T, LIPPONEN P et al.: Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res. (1998) 18:615-618.
   PubMedGoogle Scholar
• NIO Y, DONG M, IGUCHI C et al.: Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J. Surg. Oncol. (2001) 76:188-196.
   PubMed Web of Science ®Google Scholar
• DERGHAM T, DUGAN MC, KUCWAY R et al.: Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int. J. Pancreatol. (1997) 21(2):127-143.
   PubMedGoogle Scholar
• KAWESHA A, GHANEH P, ANDREN-SANDBERG A et al.: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int. J. Cancer (2000) 89(6):469-474.
   PubMed Web of Science ®Google Scholar
• CAMPANI D, BOGGI U, CECCHETTI D et al.: p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer. Pancreas (1999) 19:26-32.
   PubMedGoogle Scholar
• YOKOYAMA M, YAMANAKA Y, FRIESS H et al.: p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res. (1994) 14(6B):2477-2483.
   PubMedGoogle Scholar
• HU YX, WATANABE H, OHTSUBO K et al.: Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br. J. Cancer (1999) 80:1075-1079.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, RUGGERI B, AGARWAL P et al.: Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch. Pathol. Lab. Med. (1994) 1182:150-154.
   PubMedGoogle Scholar
• DONG M, NIO Y, TAMURA K et al.: Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese and Western patients. Cancer Epidemiol. Biomark. Prev. (2000) 9:279-284.
   PubMedGoogle Scholar
• DONG M, NIO Y, YAMASAWA K et al.: p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J. Surg. Oncol. (2003) 82:111-120.
   PubMed Web of Science ®Google Scholar
• RUGGERI BA, HUANG L, BERGER D et al.: Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer (1997) 79(4):700-716.
   PubMed Web of Science ®Google Scholar
• SINICROPE FA, EVANS DB, LEACH SD et al.: Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin. Cancer Res. (1996) 2(12):2015-2022.
   PubMedGoogle Scholar
• NAKAMORI S, YASHIMA K, MURAKAMI Y et al.: Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J. Cancer Res. (1995) 86(2):174-181.
   PubMedGoogle Scholar
• LUNDIN J, NORDLING S, VON BOGUSLAWSKY K et al.: Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology (1996) 52(2):104-111.
   Google Scholar
• LIGGETT WH, SIDRANSKY D: Role of the p16 tumour suppressor gene in cancer. J. Clin. Oncol. (1998) 16:1197-1203.
   PubMed Web of Science ®Google Scholar
• ROZENBLUM E, SCHUTTE M, GOGGINS M et al.: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. (1997) 57:1731-1734.
   PubMed Web of Science ®Google Scholar
• GERDES B, RAMASWAMY A, ZIEGLER A et al.: p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann. Surg. (2002) 235(1):51-59.
   PubMedGoogle Scholar
• BIANKIN AV, MOREY AL, LEE C et al.: DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J. Clin. Oncol. (2002) 20:4531-4542.
   PubMed Web of Science ®Google Scholar
• HU YX, WATANABE H, OHTSUBO K et al.: Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin. Cancer Res. (1997) 3(9):1473-1477.
   PubMedGoogle Scholar
• OHTSUBO K, WATANABE H, YAMAGUCHI Y et al.: Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. J. Gastroenterol. (2003) 38(7):663-671.
   PubMedGoogle Scholar
• JEONG J, PARK YN, PARK JS, YOON DS, CHI HS, KIM BR: Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med. J. (2005) 46(4):519-525.
   PubMedGoogle Scholar
• MASSAGUE J, BLAIN SW, LO RS: TGF-β signalling in growth control, cancer, and heritable disorders. Cell (2000) 103:295-309.
   PubMed Web of Science ®Google Scholar
• HAHN SA, SCHUTTE M, HOQUE AT et al.: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 271(5247):350-353.
   PubMed Web of Science ®Google Scholar
• TANG H, ZOU SQ, HAO YH et al.: The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma. Hepatobiliary Pancreat. Dis. Int. (2002) 1(4):624-629.
   PubMedGoogle Scholar
• HUA Z, ZHANG YC, HU XM, JIA ZG: Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J. Gastroenterol. (2003) 9:2764-2767.
   PubMedGoogle Scholar
• TASCILAR M, SKINNER HG, ROSTY C et al.: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res. (2001) 7:4115-4121.
   PubMed Web of Science ®Google Scholar
• BARBACID M: Ras genes. Annu. Rev. Biochem. (1987) 56:779-827.
   PubMed Web of Science ®Google Scholar
• SHERR CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. (2000) 60(14):3689-3695.
   PubMed Web of Science ®Google Scholar
• GRUNEWALD K LYONS J, FROHLICH A et al.: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer (1989) 43:1037-1041.
   PubMed Web of Science ®Google Scholar
• DERGHAM ST, DUGAN MC, KUCWAY R et al.: Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int. J. Pancreatol. (1997) 21(2):127-143.
   PubMedGoogle Scholar
• SONG MM, NIO Y, DONG M et al.: Comparison of K-ras mutation at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients. J. Surg. Oncol. (2000) 75:176-185.
   PubMedGoogle Scholar
• SONG MM, NIO Y, SATO Y et al.: Clinicopathological significance of K-ras point mutation and expression in benign and malignant exocrine tumours of the human pancreas. Int. J. Pancreatol. (1996) 20:85-93.
   PubMedGoogle Scholar
• ALLISON DC, PIANTADOSI S, HRUBAN RH et al.: DNA content and other factors associated with 10-year survival after resection of pancreatic carcinoma. J. Surg. Oncol. (1998) 6:151-159.
   Google Scholar
• KITAGO M, UEDA M, AIRURA K et al.: Comparison of K-ras mutation distributions in intraductal papillary mucinous tumours and ductal adenocarcinoma of the pancreas. Int. J. Cancer (2004) 10:177-182.
   Google Scholar
• MOTOJIMA K, URANO T, NAGATA Y et al.: Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumour stage in human pancreatic carcinoma. Am. J. Gastroenterol. (1991) 86:1784-1788.
   PubMedGoogle Scholar
• FINKELSTEIN SD, PRZYGODZKI RM, PRICOLO VE et al.: K-ras-2 topographic genotyping of pancreatic adenocarcinoma. Arch. Surg. (1994) 129:367-372.
   PubMed Web of Science ®Google Scholar
• HRUBAN RH, VAN MANSFIELD AD, OFFERHAUS G et al.: K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant enriched chain reaction analysis and allele specific oligonucleotide hybridization. Am. J. Pathol. (1993) 143:545-554.
   PubMed Web of Science ®Google Scholar
• JUUTI A, NORDLING S, LOUHIMO J et al.: Loss of p27 expression is associated with poor prognosis in stage I – II pancreatic cancer. Oncology (2003) 65:371-377.
   PubMed Web of Science ®Google Scholar
• LU CD, MORITA S, ISHIBASHI T et al.: Loss of p27-kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer (1999) 85:1250-1260.
   PubMed Web of Science ®Google Scholar
• FU M, WANG C, LI Z, SAKAMAKI T, PESTELL RG: Minireview: cyclin D1: normal and abnormal functions. Endocrinology (2004) 145(12):5439-5447.
   PubMed Web of Science ®Google Scholar
• LI YJ, JI XR: Relationship between the expression of β-catenin, cyclin D1 and myc and the occurrence and biological behaviour of pancreatic cancer. Zhonghua Bing Li Xue Za Zhi (2003) 32:238-241.
   PubMedGoogle Scholar
• QIAO Q, RAMADANI M, GANSAUGE S et al.: Reduced membranous and ectopic cytoplasmic expression of β-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int. J. Cancer (2001) 95:194-197.
   PubMed Web of Science ®Google Scholar
• GANSAUGE F, GANSAUGE S, SCHMIDT E et al.: Prognostic significance of molecular alterations in human pancreatic carcinoma: an immunological study. Langebecks Arch. Surg. (1998) 383:152-155.
   PubMedGoogle Scholar
• KAWESHA A, GHANEH P, ANDREN-SANDBERG A et al.: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int. J. Cancer (2000) 89(6):469-474.
   PubMed Web of Science ®Google Scholar
• KORNMANN M, ISHIWATA T, ITAKURA J et al.: Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology (1998) 55(4):363-369.
   PubMed Web of Science ®Google Scholar
• GANSAUGE S, GANSUAGE F, RAMADANI M et al.: Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. (1997) 57:1634-1637.
   PubMed Web of Science ®Google Scholar
• JACOBSON MD, WEIL M, RAFF MC: Programmed cell death in animal development. Cell (1997) 88:347-354.
   PubMed Web of Science ®Google Scholar
• ASHKENAZI A, DIXIT VM: Death receptors: signaling and modulation. Science (1998) 281:1305-1308.
   PubMed Web of Science ®Google Scholar
• GREEN DR, REED JC: Mitochondria and apoptosis. Science (1998) 281:1309-1312.
   PubMed Web of Science ®Google Scholar
• BURLACU A: Regulation of apoptosis by Bcl-2 family proteins. J. Cell Mol. Med. (2003) 7(3):249-257.
   PubMed Web of Science ®Google Scholar
• SUN CY, WANG BL, HU CQ et al.: Expression of the bcl-2 gene and its significance in human pancreatic cancer. Hepatobiliary Pancreat. Dis. Int. (2002) 1:306-308.
   PubMedGoogle Scholar
• NIO Y, IGUCHI C, YAMASAWA K et al.: Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas (2001) 22:230-239.
   PubMedGoogle Scholar
• NIO Y, DONG M, IGUCHI C et al.: Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J. Surg. Oncol. (2001) 76:188-196.
   PubMed Web of Science ®Google Scholar
• EVANS JD, CORNFORD PA, DODSON A et al.: Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology (2001) 1:254-262.
   PubMedGoogle Scholar
• HU YX, WATANABE H, OHTSUBO K et al.: Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br. J. Cancer (1999) 80:1075-1079.
   PubMed Web of Science ®Google Scholar
• FRIESS H, LU Z, GRABER HU et al.: Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut (1998) 43:414-421.
   PubMed Web of Science ®Google Scholar
• FRIESS H, LU Z, ANDREN-SANDBERG A et al.: Moderate activation of the apoptosis inhibitor bcl-xL worsens prognosis in pancreatic cancer. Ann. Surg. (1998) 228:780-787.
   PubMed Web of Science ®Google Scholar
• OHSHIO G, SUWA H, IMMAMURA T et al.: An immunohistochemical study of blc-2 and p53 protein expression in pancreatic carcinomas. Scand. J. Gastroenterol. (1998) 33:535-539.
   PubMedGoogle Scholar
• MAKINEN K, HAKALA T, LIPPONEN P et al.: Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res. (1998) 18:615-618.
   PubMedGoogle Scholar
• SINICROPE FA, EVANS DB, LEACH SD et al.: Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin. Cancer Res. (1996) 2(12):2015-2022.
   PubMedGoogle Scholar
• DONG M, ZHOU JP, ZHANG H, GUO KJ, TIAN YL, DONG YT: Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J. Gastroenterol. (2005) 11(18):2744-2747.
   PubMedGoogle Scholar
• MAGISTRELLI P, COPPOLA R, TONINI G et al.: Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J. Cell Biochem. (2006) 97(1):98-108.
   PubMedGoogle Scholar
• CROW MT: Hypoxia. BNip3 proteins, and the mitochondrialdeath pathway in cardiomyocytes. Circ. Res. (2002) 91:183-185.
   PubMed Web of Science ®Google Scholar
• ERKAN M, KLEEFF J, ESPOSITO I et al.: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene (2005) 24(27):4421-4432.
   PubMed Web of Science ®Google Scholar
• LACASSE EC, BAIRD S, KORNELUK RG, MACKENZIE AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene (1998) 17:3247-3259.
   PubMed Web of Science ®Google Scholar
• KAMI K, DOI R, KOIZUMA M et al.: Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery (2004) 136:443-448.
   PubMed Web of Science ®Google Scholar
• TONINI G, VINCENZI B, SANTINI D et al.: Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br. J. Cancer (2005) 92(12):2225-2232.
   PubMed Web of Science ®Google Scholar
• LIOTTA LA, RAO CN, BARSKY SH: Tumor invasion and the extracellular matrix. Lab. Invest. (1983) 49:636-649.
   PubMed Web of Science ®Google Scholar
• LAFLAMME SE, AUER KL: Integrin signalling. Semin. Cancer Biol. (1996) 7:111-118.
   PubMedGoogle Scholar
• FRISCH SM, RUOSLAHTI E: Integrin and anoikis. Curr. Opin. Cell Biol. (1997) 9(5):701-707.
   PubMed Web of Science ®Google Scholar
• VARGHESE S: Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions. Front. Biosci. (2006) 11:2949-2966.
   PubMed Web of Science ®Google Scholar
• HARVEY SR, HURD TC, MARKUS G et al.: Evaluation of urinary plasminogen activator, its receptor matrix metalloproteinase-9 and von Willebrand factor in pancreatic cancer. Clin. Cancer Res. (2003) 9(13):4935-4943.
   PubMed Web of Science ®Google Scholar
• NAKAMURA H, HORITA S, SENMARU N et al.: Association of matrilysin expression with progression and poor prognosis in human pancreatic adenocarcinoma. Oncol. Rep. (2002) 9:751-755.
   PubMedGoogle Scholar
• YAMMAMOTO H, ITAH F, IKU S et al.: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J. Clin. Oncol. (2001) 19:1118-1127.
   PubMedGoogle Scholar
• MAATA M, SOINI Y, LIAKKA A et al.: Differential expression of matrix metalloproteinase (MMP)-2 and 9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumour progression and clinical prognosis. Clin. Cancer Res. (2000) 6:2726-2734.
   PubMedGoogle Scholar
• GONG YL, XU GM, HUANG WD et al.: Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J. Surg. Oncol. (2000) 73:95-99.
   PubMed Web of Science ®Google Scholar
• ITO T, ITO M, SHIOZAWA J et al.: Expression of MMP-1 in human pancreatic carcinoma: relationship with prognostic factors. Mod. Pathol. (1999) 12:669-674.
   PubMed Web of Science ®Google Scholar
• KOSHIBA T, HOSOTANI R, WADA M et al.: Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer (1998) 82:642-650.
   PubMed Web of Science ®Google Scholar
• JONES LE, HUMPHREYS MJ, CAMPBELL F, NEOPTOLEMOS JP, BOYD MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin. Cancer Res. (2004) 10(8):2832-2845.
   PubMed Web of Science ®Google Scholar
• GRUTZMANN R, LUTTGES J, SIPOS B et al.: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer (2004) 90(5):1053-1058.
   PubMed Web of Science ®Google Scholar
• IKEDA N, NAKAJIMA Y, TOKUHARA T et al.: Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin. Cancer Res. (2003) 9(4):1503-1508.
   PubMed Web of Science ®Google Scholar
• SHIMAMURA T, SAKAMOTO M: Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to E-cadherin expression. J. Clin. Oncol. (2003) 21(4):659-667.
   PubMedGoogle Scholar
• BEAUVAIS DM, RAPRAEGER AC: Syndecans in tumor cell adhesion and signaling. Reprod. Biol. Endocrinol. (2004) 2:3.
   PubMedGoogle Scholar
• JUUTI A, NORDLING S, LUNDIN J, LOUHIMO J, HAGLUND C: Syndecan-1 expression – a novel prognostic marker in pancreatic cancer. Oncology (2005) 68(2-3):97-106.
   PubMed Web of Science ®Google Scholar
• BORNSTEIN P, AGAH A, KYRIAKIDES TR: The role of thrombospondins 1 and 2 in the regulation of cell–matrix interactions, collagen fibril formation, and the response to injury. Int. J. Biochem. Cell Biol. (2004) 36(6):1115-1125.
   PubMed Web of Science ®Google Scholar
• TOBITA K, KIJIMA H, DOWAKI S et al.: Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int. J. Oncol. (2002) 21(6):1189-1195.
   PubMed Web of Science ®Google Scholar
• SAITOU M, GOTO M, HORINOUCHI M et al.: MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J. Clin. Pathol. (2005) 58(8):845-852.
   PubMed Web of Science ®Google Scholar
• MASUI T, DOI R, KOSHIBA T et al.: RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin. Cancer Res. (2003) 9(5):1779-1784.
   PubMedGoogle Scholar
• UEHARA H, MIYAMOTO M, KATO K et al.: Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res. (2004) 64:3533-3537.
   PubMed Web of Science ®Google Scholar
• NITORI N, INO Y: Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin. Cancer Res. (2005) 11:2531-2539.
   PubMed Web of Science ®Google Scholar
• SHIMAMURA T, SAKAMOTO M: Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin. Cancer Res. (2002) 8:2570-2575.
   PubMed Web of Science ®Google Scholar
• GUAN UL: The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal. (1994) 6:581-589.
   PubMed Web of Science ®Google Scholar
• HILL CS, TREISMAN R: Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell (1995) 80:199-211.
   PubMed Web of Science ®Google Scholar
• ITOH S, ITOH F, GOUMANS MJ, TEN DIJKE P: Signaling of transforming growth factor-β family members through Smad proteins. Eur. J. Biochem. (2000) 267(24):6954-6967.
   PubMedGoogle Scholar
• FRIESS H, BERBERAT P, SCHILLING M, KUNZ J, KORC M, BUCHLER MW: Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J. Mol. Med. (1996) 74:35-42.
   PubMedGoogle Scholar
• LAKSHMIKESARI A, RADHAKRISHNA R, BRANUMATHI A et al.: Expression of epidermal andtransforming growth factors in pancreatic cancer. Oncol. Rep. (1996) 3:963-966.
   PubMedGoogle Scholar
• HASHIMOTO Y, NIO Y, SUMI S et al.: Correlation between TGF-β1 and p21 (WAFI/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. Pancreas (2001) 22:341-371.
   PubMed Web of Science ®Google Scholar
• WAGNER M, KLEEFF J, FRIESS H et al.: Enhanced expression of the type II TGF-β1 receptor is associated with decreased survival in human pancreatic cancer. Pancreas (1999) 19:370-376.
   PubMedGoogle Scholar
• COPPOLA D, LU L, FREHAUF JP et al.: Analysis of p53, p21WAF1, and TGF-β1 in human ductal adenocarcinoma of the pancreas: TGF-β1 protein expression predicts longer survival. Am. J. Clin. Pathol. (1998) 110:16-23.
   PubMed Web of Science ®Google Scholar
• FRIESS H, YAMANAKA Y, BUCHLER M et al.: Enhanced expression of TGF-β isoform-2 in pancreatic cancer correlates with decreased survival. Gastroenterology (1993) 105:1846-1856.
   PubMed Web of Science ®Google Scholar
• OZAWA F, FRIESS H, TEMPIA-CALIERA A, KLEEFF J, BUCHLER MW: Growth factors and their receptors in pancreatic cancer. Teratog. Carcinog. Mutag. (2001) 21(1):27-44.
   PubMedGoogle Scholar
• YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Co-expression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumour aggressiveness. Anticancer Res. (1993) 13:565-570.
   PubMed Web of Science ®Google Scholar
• UEGAKI K, NIO Y, INOUE S et al.: Clinicopathological significance of epidermal growth factor and receptor in human pancreatic cancer. Anticancer Res. (1997) 17:3841-3847.
   PubMed Web of Science ®Google Scholar
• YAMANAKA Y: The immunohistochemical expressions of epidermal growth factor, epidermal growth factor receptors and c-erbB2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi (1992) 59:51-61.
   PubMedGoogle Scholar
• YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Co-expression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumour aggressiveness. Anticancer Res. (1993) 13:565-570.
   PubMed Web of Science ®Google Scholar
• UEDA M, OGATA S, TSUDA H et al.: The correlation between cytoplasmic overexpression of epidermal growth factor and tumour aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas (2004) 29:1-8.
   PubMed Web of Science ®Google Scholar
• TAMIOLAKIS D, VENIZELOS I, SIMOPOULOS C et al.: Correlation of immunohistochemically detected HER-2/neu (erbB-2) with histological stage and perineural invasion in pancreatic cancer. Hepatogastroenterology (2004) 51:334-337.
   PubMedGoogle Scholar
• TOBITA K, KIJIMA H, DOWAKI S et al.: Epidermal growth factor expression in human pancreatic carcinoma: significance for liver metastasis. Int. J. Mol. Med. (2003) 11:305-309.
   PubMed Web of Science ®Google Scholar
• ZHANG H, YUAN SZ: Expression of c-erbB2 oncogene protein, epidermal growth factor receptor and TGF-β1 in human pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat. Dis. Int. (2002) 1:620-623.
   PubMedGoogle Scholar
• KOKA V, POTTI A, KOCH M et al.: Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression of pancreatic carcinoma. Anticancer Res. (2002) 22:1593-1597.
   PubMedGoogle Scholar
• THYBUSCH-BERNHARDT, BECKMANN S, JUHL H: Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumour stage. Int. J. Surg. Invest. (2001) 2:393-400.
   PubMedGoogle Scholar
• SAFRAN H, STEINHOFF M, MANGRAY S et al.: Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. (2001) 24:496-499.
   Google Scholar
• NOVOTNY J, PETRUZELKA L, VEDRALOVA J et al.: Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma (2001) 48:188-191.
   PubMedGoogle Scholar
• GRABER HU, FRIESS H, KAUFMANN B et al.: ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. Int. J. Cancer (1999) 84:24-27.
   PubMed Web of Science ®Google Scholar
• DUGAN MC, DERGHAM ST, KUCWAY R et al.: HER-2/neu expression in pancreatic adenocarcinoma: relationship to tumour differentiation and survival. Pancreas (1997) 14:229-236.
   PubMed Web of Science ®Google Scholar
• OKADA N, OHSHIO G, YAMAKI K et al.: Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. Oncology (1995) 52(5):392-396.
   PubMed Web of Science ®Google Scholar
• LEI S, APPERT HE, NAKATA B et al.: Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int. J. Pancreatol. (1995) 17:15-21.
   PubMedGoogle Scholar
• BYRNE AM, BOUCHIER-HAYES DJ, HARMEY JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell Mol. Med. (2005) 9(4):777-794.
   PubMed Web of Science ®Google Scholar
• KURAHARA H, TAKAO S, MAEMURA K, SHINCHI H, NATSUGOE S, AIKOU T: Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin. Cancer Res. (2004) 10(24):8413-8412.
   PubMed Web of Science ®Google Scholar
• BUCHLER P, REBER HA, BUCHLER MW et al.: VEGF-RII influences the prognosis of pancreatic cancer. Ann. Surg. (2002) 236:738-749.
   PubMed Web of Science ®Google Scholar
• NIEDERGETHMANN M, HILDENBRAND R, WOSTBROCK B et al.: High expression of vascular endothelial growth factor predicting early recurrence and poor prognosis after curative resection of ductal adenocarcinoma of the pancreas. Pancreas (2002) 25:122-129.
   PubMed Web of Science ®Google Scholar
• SEO Y, BABA H, FUKUDA T et al.: High expression of vascular endothelial growth factor is associated with liver metastasis and poor prognosis for patients with ductal adenocarcinoma. Cancer (2000) 88:2239-2245.
   PubMed Web of Science ®Google Scholar
• IKEDA N, ADACHI M, TAKI T et al.: Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer (1999) 79:1553-1563.
   PubMed Web of Science ®Google Scholar
• MACDONALD PM, STRUHL G: A molecular gradient in early Drosophila embryos and its role in specifying the body pattern. Nature (1986) 324:537-545.
   PubMedGoogle Scholar
• SUH E, CHEN L, TAYLOR J, TRABER PG: A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol. Cell Biol. (1994) 14:7340-7351.
   PubMed Web of Science ®Google Scholar
• DRUMMOND F, PUTT W, FOX M, EDWARDS YH: Cloning and chromosome assignment of the human CDX2 gene. Ann. Hum. Genet. (1997) 61(5):393-400.
   PubMedGoogle Scholar
• MATSUMOTO K, MIZOSHITA T, TSUKAMOTO T: Cdx2 expression in pancreatic tumors: relationship with prognosis of invasiveductal carcinomas. Oncol. Rep. (2004) 12(6):1239-1243.
   PubMedGoogle Scholar
• KIM J, REBER HA, HINES OJ et al.: The clinical significance of MAGEA3 expression in pancreatic cancer. Int. J. Cancer (2006) 118(9):2269-2275.
   PubMedGoogle Scholar
• ENJOJI M, NAKASHIMA M, YAMAGUCHI K, KOTOH K, NAKAMUTA M: Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas. J. Gastroenterol. Hepatol. (2005) (8):1143-1148.
   PubMedGoogle Scholar
• HIRAOKA K, HIDA Y, MIYAMOTO M et al.: High expression of tumor-associated antigen RCAS1 in pancreatic ductaladenocarcinoma is an unfavorable prognostic marker. Int. J. Cancer (2002) 99(3):418-423.
   PubMedGoogle Scholar
• JI P, GOLDIN L, REN H et al.: SKP2 contains a novel cyclin a binding domain that directly protects cyclin A from inhibition by p27Kip1. J. Biol. Chem. (2006) 281(33):24058-24069.
   PubMedGoogle Scholar
• EINAMA T, KAGATA Y, TSUDA H et al.: High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlationwith the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas (2006) 32(4):376-381.
   PubMedGoogle Scholar
• SHIBAJI T, NAGAO M, IKEDA N et al.: Prognostic significance of HIF-1α overexpression in human pancreaticcancer. Anticancer Res. (2003) 23(6C):4721-4727.
   PubMed Web of Science ®Google Scholar
• TEZEL E, HIBI K, NAGASAKA T, NAKAO A: PGP9.5 as a prognostic factor in pancreatic cancer. Clin. Cancer Res. (2000) 6(12):4764-4767.
   PubMed Web of Science ®Google Scholar
• VIMALACHANDRAN D, GREENHALF W, THOMPSON C et al.: High nuclear S100A6 (calcyclin) is significantly associated with poor survivalin pancreatic cancer patients. Cancer Res. (2005) 65(8):3218-3225.
   PubMed Web of Science ®Google Scholar
• SONG G, OUYANG G, BAO S: The activation of Akt/PKB signaling pathway and cell survival. J. Cell Mol. Med. (2005) 9(1):59-71.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO S, TOMITA Y, HOSHIDA Y et al.: Prognostic significance of activated Akt expression in pancreatic ductaladenocarcinoma. Clin. Cancer Res. (2004) 10(8):2846-2850.
   PubMed Web of Science ®Google Scholar
• SUZUOKI M, MIYAMOTO M, KATO K et al.: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br. J. Cancer (2002) 87(10):1140-1144.
   PubMed Web of Science ®Google Scholar
• GOTTESMAN MM, FOJO T, BATES SE : Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer (2002) 2:48-58.
   PubMed Web of Science ®Google Scholar
• LU Z, KLEEFF J, SHRIKHANDE S et al.: Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas (2000) 21(3):240-247.
   PubMed Web of Science ®Google Scholar
• SUWA H, OHSHIO G, ARAO S et al.: Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Jpn J. Cancer Res. (1996) 87(6):641-649.
   PubMedGoogle Scholar
• MACDONALD JS, MCCOY S, WHITEHEAD RP et al.: A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest. New Drugs (2005) 23:485-487.
   PubMed Web of Science ®Google Scholar
• HEZEL AF, KIMMELMAN AC, STANGER BZ, BARDEESY N, DEPINHO RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. (2006) 20:1218-1249.
   PubMed Web of Science ®Google Scholar
• XIONG HQ: Molecular targeting therapy for pancreatic cancer. Cancer Chemother. Pharmacol. (2004) 54(Suppl. 1):S69-S77.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, ROSEMURGY A, BROWN PD et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer; a randomized trial. J. Clin. Oncol. (2001) 19:3447-3455.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, SCHULZ J, NEMUNAITIS J et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer (2002) 87:161-167.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a Phase III trial of the National cancer institute of Canada clinical trials group (NCIC-CTG). Program and Abstracts of the 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (27 – 29 January 2005), Hollywood, Florida, USA (2005):(Abstract 77).
   Google Scholar
• WACKER B, NAGRANI T, WEINBERG J, WITT K, CLARK G, CAGNONI PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large Phase III studies. Clin. Cancer Res. (2007) 13(13):3913-3921.
   PubMed Web of Science ®Google Scholar
• SINGH A, MONIAUX, N, CHAUHAN S et al.: Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. (2004) 64:622-630.
   PubMed Web of Science ®Google Scholar
• SINGH AP, CHATURVEDI P, BATRA SK: Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res. (2007) 67:433-436.
   PubMed Web of Science ®Google Scholar
• KINDLER HL, NIEDZWIECKI D, HOLLIS D et al.: A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB) 80303. Program and Abstracts of the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (17 – 21 January 2007), Orlando, Florida, USA (2007):(Abstract 108).
   Google Scholar